Fisher Andrew's Form 4/A amendment
AmendedVerona Pharma plc (VRNA) · filed Jun 18, 2025
- Accession no.
- 0001104659-25-060648
- Filed
- Jun 18, 2025
- Trade date
- May 15, 2025
- Filing delay
- 34 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- May 16, 2025
This filing lists 1 non-derivative transaction and 1 derivative transaction. It carries over 1 transaction from the original filing that it did not restate. Open-market sales total $685.6K. It was filed 34 days after the trade.
This amendment restates part of 0001104659-25-050047 (filed May 16, 2025). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Fisher AndrewCIK 0002014301 | Officer (General Counsel) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 15, 2025 | Ordinary Shares | MOption exerciseAcquired | +80,000 | $2.01F1 | +$160,800 | 439,999 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 15, 2025 | Ordinary Shares | MOption exerciseDisposed | −80,000 | $0.00 | $0 | 2,320,000 | Direct |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001104659-25-050047 (filed May 16, 2025).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 15, 2025 | Ordinary Shares | SSaleDisposed | −80,000 | $8.57F3 | −$685,600 | 359,999 | Direct |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F3
The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $8.3863 to $8.6913 per Ordinary Share, inclusive (or $67.09 to $69.53 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This amendment is being filed to correct the Reporting Person's Form 4 filed on May 16, 2025, which contained a typographical error in the price reported.
Referenced by the price of 1 transaction in Table I.
- F2
Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
- F3
The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer.
- F4
The option vested and became exercisable as to 25% on March 4, 2025. The remainder of the shares vested or will vest in 36 equal monthly installments thereafter.